Subcutaneous sumatriptan during the migraine aura

Abstract

This double-blind, placebo-controlled, multicenter, parallel-group study assessed whether subcutaneous sumatriptan administered during the migraine aura would prolong or modify the aura and prevent or delay development of the headache. One hundred seventy-one patients (88 receiving 6 mg sumatriptan, 83 receiving placebo) treated a single attack of migraine with typical aura at home, by self-injection. The median duration of aura following the first injection was 25 minutes for the sumatriptan group and 30 minutes for the placebo group (NS). The aura symptom profile was similar for the two treatment groups. The proportion of patients who developed a moderate or severe headache within 6 hours after dose administration was similar in the two groups--68% among those receiving sumatriptan and 75% among those receiving placebo (NS). Sumatriptan given during the aura did not prolong or alter the nature of the migraine aura and did not prevent or significantly delay headache development.

Современные Подходы К Фармакотерапии Мигрени

“…Со-гласно данным международных исследований, около 15-40 % пациентов, принимающих перорально триптан, испытывают рецидивы [32,35,36]. Ïðàêòèêóþ÷îìó íåâðîëîãó /To Practicing Neurologist/ Эрготамин раньше был основным препаратом в ле-чении мигрени, но в настоящее время он не относится к препаратам выбора для купирования острых мигре-нозных приступов.…”

Sumatriptan (Subcutaneous Route of Administration) for Acute Migraine Attacks in Adults

“…Of the remaining studies, one (Bates 1994) required participants to administer medication at the onset of aura, one (S2BM03) at the onset of migraine, and one (S2BS78) at the first sign of headache pain. Seven studies did not report the baseline headache intensity at which study medication was administered.…”

“…• Sumatriptan 6 mg versus placebo (Akpunonu 1995;Bates 1994;Bousser 1993;Cady 1991 Study 1 and Study 2;Cady 1993;Cady 1998;Dahlof 1998;Diener 1999;Diener 2001;Facchinetti 1995;Ferrari 1991;Gross 1994;Henry 1993;Jensen 1995;Mathew 1992;Mushet 1996 • Sumatriptan 6 mg versus subcutaneous naratriptan 0.5 mg (Dahlof 1998). …”

“…We considered no studies to be at high risk of bias from random sequence generation, allocation concealment, or blinding. Fifteen studies (Akpunonu 1995;Bates 1994;Bousser 1993;Cady 1993;Dahlof 1992;Dahlof 1998;Diener 1999;Gross 1994;Henry 1993;Mathew 1992;Mushet 1996 Study 1 and Study 2;Sang 2004;Schulman 2000;Thomson 1993) did not include 50 or more participants in each treatment arm and we therefore considered them to be at high risk of bias from their size.…”

Combining therapies for the treatment of migraine: is there a role?

“…Monotherapy using these agents does not result in rapid, consistent and complete relief of migraine and migraine aura in all patients [19,20]. Up to 31% of patients taking a triptan may discontinue its use due to lack of efficacy, headache recurrence, cost and/or side effects [21][22][23].…”